Who are placebo + PEGinterferon alfa-2a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Besremi, INF1.0 + IBU, PEG -Intron, Reiferon retard, Rosiglitazone and Pegasys/Ribavirin, Reiferon Retard in Arm 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-peginterferon-alfa-2a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

placebo + PEGinterferon alfa-2a — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

placebo + PEGinterferon alfa-2a (placebo + PEGinterferon alfa-2a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alfa. Area: Immunology.

phase 3 Interferon alfa Interferon-alpha receptor (IFNAR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

placebo + PEGinterferon alfa-2a (placebo + PEGinterferon alfa-2a) — SciClone Pharmaceuticals. PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
placebo + PEGinterferon alfa-2a TARGET	placebo + PEGinterferon alfa-2a	SciClone Pharmaceuticals	phase 3	Interferon alfa	Interferon-alpha receptor (IFNAR)
Besremi	ROPEGINTERFERON ALFA-2B	Pharma Essentia Corporation	marketed	Interferon alfa-2b [EPC]	Interferon alpha/beta receptor	2021-01-01
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2
PEG -Intron	PEG -Intron	Beth Israel Deaconess Medical Center	marketed	Pegylated interferon alfa	Interferon-alpha receptor (IFNAR)
Reiferon retard	Reiferon retard	MinaPharm Pharmaceuticals	marketed	Interferon alfa-2a (long-acting/sustained-release formulation)	Type I interferon receptor (IFNAR)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
Reiferon Retard in Arm 1	Reiferon Retard in Arm 1	MinaPharm Pharmaceuticals	marketed	Interferon alfa-2a (long-acting/sustained-release)	Type I interferon receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alfa class)

Barbara Ann Karmanos Cancer Institute · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
SciClone Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo + PEGinterferon alfa-2a — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-peginterferon-alfa-2a. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab